Idenix Pharmaceuticals, Inc. is engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix’s current focus is on the treatment of hepatitis C virus (HCV) infections. The company has previously discovered and developed antivirals for the treatment of hepatitis B virus (HBV) and HIV/AIDS.
Idenix discovered, co-developed and co-launched telbivudine (Tyzeka®/Sebivo®) for the treatment of HBV, for which Novartis Pharma AG now has worldwide commercialization rights.
Idenix has focused its efforts towards HCV due to the global unmet medical need for this viral disease. It is estimated that more than 150 million people worldwide are chronically infected with HCV.
Idenix is headquartered in Cambridge, Massachusetts (MA). Its clinical development operations and drug discovery operations are conducted in Cambridge, MA and the company’s European laboratories are located in Montpellier, France.